0 results available. Select is focused ,type to refine list, press Down to open the menu,
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, H...
The following section summarizes insights on Eli Lilly and Company's Total Debt / Total Capital:
We've identified the following companies as similar to Eli Lilly and Company because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Total Debt / Total Capital in the risk category include:
A ratio that measures the level of the debt relative to the market value of total capital.
Total Debt / Total Capital is defined as:
Total Capital = Market Cap + Total Debt
Total Debt / Total Capital = Total Debt / Total Capital
The higher the percentage, the more debt the company has in its capital structure and the lower the equity cushion. In times of distress, a high Debt / Total Capital increases the chances of default or bankruptcy.
The chart above depicts the distribution of total debt / total capital for companies operating in the Healthcare sector in the Developed economic region. Over 2,450 companies were considered in this analysis, and 2,402 had meaningful values. The average total debt / total capital of companies in the sector is 19.6% with a standard deviation of 23.5%.
Eli Lilly and Company's Total Debt / Total Capital of 5.0% ranks in the 40.4% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,452 |
| Included Constituents | 2,402 |
| Min | 0.0% |
| Max | 94.6% |
| Median | 9.6% |
| Mean | 19.6% |
| Standard Deviation | 23.5% |
You can find companies with similar total debt / total capital using this stock screener.